NattoPharma ASA has announced that its patent application, #09/850,804 (“ex-Unilver”) re. “Vitamin K2 Containing Food product,” has been approved and issued in the U.S. by the United States Patent and Trade Office.
According to Dr. Hogne Vik, CEO of NattoPharma, this new patent will strengthen NattoPharma's IPR and commercial platform in the U.S. The patent will give NattoPharma a broad coverage on the use of menaquinones (vitamin K2) in the preparation of a food product (including dietary supplements) for maintaining, optimizing, strengthening or promoting cardiovascular health.
"The approval of the patent represents a milestone for NattoPharma and our partners in the U.S. market. This will strengthen NattoPharma's global IPR platform and improve our competitive position in the United States within the food supplement market as well as the functional food market," says Vik.